ArticleJournal of veterinary internal medicine2026
Plasma proteomic profiling in dogs with pheochromocytoma.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPheochromocytomas (PCCs) in dogs are challenging to diagnose. Plasma proteomics offers a minimally invasive approach to identify circulating biomarkers and disease-relevant pathways. HYPOTHESIS/
objectivesTo compare the plasma proteome of dogs with PCC and controls to (1) identify differentially abundant proteins, (2) characterize altered pathways, and (3) nominate candidate circulating biomarkers and therapeutic targets. ANIMALS: Plasma from 10 client-owned PCC dogs and 10 healthy controls.
methodsMulticenter, retrospective, observational, exploratory study using label-free liquid chromatography-mass spectrometry. Primary outcomes were the identification of differentially abundant proteins and characterization of altered pathways and protein functions.
resultsPrincipal component analysis demonstrated clear separation between PCC and control dogs. Of 261 reliably quantified proteins, 51 were differentially abundant (false discovery rate-adjusted P < .05). Of these, 33 had a log2 fold change of >1 or < -1, with 15 showing higher and 18 lower plasma abundance in PCC. Compared with controls, PCC dogs showed increased abundance of proteins linked to cell adhesion/migration and metastatic potential, hemostasis, and regulation of apoptotic signaling, alongside alterations in oxidative stress and metabolic processes. Several proteins with higher abundance, including CD44, peroxiredoxin-2, and peptidyl-prolyl cis-trans isomerase, emerged as promising candidates for therapeutic exploration. CONCLUSIONS AND CLINICAL IMPORTANCE: Dogs with PCC exhibit a distinct circulating protein signature vs healthy controls, providing clues to PCC pathogenesis and nominating proteins as diagnostic biomarker candidates and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.